Markets:

Overview

News

Currencies

International

Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

1.610 +0.030 (+1.90%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Inovio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

Lab Study Shows Inovio's COVID-19 Vaccine Candidate Weaker Against Omicron Variant ↗

March 02, 2022

Tucked in the Q4 earnings release, Inovio Pharmaceuticals Inc (NASDAQ: INO) has paused enrollment for an ongoing INNOVATE Phase 3 trial of its lead COVID-19 vaccine...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

28 Stocks Moving in Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Inovio Pharmaceuticals: Q4 Earnings Insights ↗

March 01, 2022

Inovio Pharmaceuticals (NASDAQ:INO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 01, 2022

Gainers Organogenesis Holdings (NASDAQ:ORGO

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals? ↗

February 24, 2022

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b...

Via Benzinga

Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals ↗

January 21, 2022

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 ↗

January 21, 2022

Upgrades According to Seaport Global, the prior rating for KB Home (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

January 21, 2022

Barclays cut Netflix, Inc. (NASDAQ: NFLX) price target from $675 to $425. Netflix shares fell 19.6% to $408.58 in pre-market trading. Keybanc cut Chipotle Mexican Grill, Inc...

Via Benzinga

Bill Gates Says Misinformation Related To Fauci, Himself Doesn't 'Make Sense,' Talks COVID-19 After Omicron ↗

January 11, 2022

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates answered questions related to COVID-19 on Twitter Tuesday. What Happened: The questions to Gates were routed through...

Via Benzinga

Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street ↗

December 29, 2021

Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current

Via Talk Markets

If You Invested $1,000 In Inovio Stock One Year Ago, Here's How Much You'd Have Now ↗

December 27, 2021

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 29.2...

Via Benzinga

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Market Briefing For Thursday, Dec. 23 ↗

December 23, 2021

'Fortune favors the brave' it is said; it's partially so in this market, where we certainly got the ignition Tuesday of the seasonal rebound we looked for and more on Wednesday.

Via Talk Markets

Why Jim Cramer Likes MGM Growth Properties ↗

December 21, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE:

Via Benzinga

Why You Should Buy Moderna Stock at Every Dip ↗

December 10, 2021

Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock.

Via InvestorPlace

Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week ↗

December 03, 2021

These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant.

Via The Motley Fool

The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO ↗

December 03, 2021

The omicron variant signals a need for annual Covid shots, BioNTech's CEO said.

Via Investor's Business Daily

2 Stocks That Are Down 60% (or More) From Their 52-Week Highs ↗

December 03, 2021

One of these stocks is poised to rebound, but the other still looks very risky.

Via The Motley Fool

Topics Economy

Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat ↗

November 30, 2021

Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant.

Via Investor's Business Daily

Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail? ↗

November 29, 2021

Smaller companies are working on next-generation approaches to Covid treatment.

Via Investor's Business Daily

20 Stocks Moving in Monday's Pre-Market Session ↗

November 29, 2021

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results...

Via Benzinga

Novavax Working On New COVID-19 Vaccine To Combat Omicron Variant ↗

November 29, 2021

Novavax Inc (NASDAQ: NVAX) said it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa. It said that the shot would be...

Via Benzinga

Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen ↗

November 21, 2021

Both vaccine makers still have big hurdles to jump.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

Headline News about Inovio Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today